Valproate-induced disorders of dopamine metabolism and the development of valproate-induced parkinsonism: a new perspective on prevention and diagnosis

The problem of valproate-induced adverse drug reactions, including valproate-induced parkinsonism is of high relevance due to the widespread use of valproates in psychiatric and neurological practice and the complexity of the pathogenesis of dopaminergic neurotransmission disorders. Unfortunately, personalized algorithms for practicing physicians based on the use of modern methods of pharmacogenomics and pharmacometabolomics of valproate-induced parkinsonism have not yet been developed. The most important methods of diagnosis and prognosis of valproate-induced parkinsonism are 1) investigation of neurologic status (assessment of motor and non-motor symptoms of drug-induced parkinsonism); 2) therapeutic drug monitoring of total and free fractions of valproic acid; 3) study of the level of toxic metabolic metabolites of valproic acid in blood and urine; pharmacogenetic testing of non-functional single nucleotide variants of genes encoding key metabolic enzymes and key transport proteins of valproic acid efflux across the blood-brain barrier.

1. Bochanova EN, Gusev SD, Dmitrenko DV, Shnayder NA, Nasyrova RF. Algorithm of personalized prescription of valproic acid preparations. Doktor.Ru. 2019;6(161):6-11. (In Russ.).

2. Vaiman EE, Shnayder NA, Neznanov NG, Nasyrova RF. Drug-induced parkinsonism. Social'naya i klinicheskaya psihiatriya. 2021;31(1):96-103 (In Russ.).

3. Vaiman EE, Shnayder NA, Neznanov NG, Nasyrova RF. Diagnostic methods of antipsychotic-induced extrapyramidal disorders. Sibirskoe medicinskoe obozrenie. 2019;5(119):5-13. (In Russ.).

4. Vostrikova EV, Schepankevich LA, Pilipenko PI, Akhundova LE, Myasnikova NG, Kononova EA, Fedorova KO. Clinical characteristics of visual disturbances in Parkinson's disease. Journal of Siberian Medical Sciences. 2011;4:4. (In Russ.).

5. Govorova TG, Popova TE, Tappakhov AA. Tremorography in clinical practice. Nervno-myshechnye bolezni. 2019;9(4):61-72. (In Russ.).

6. Goncharova ZA, Gelpey MA, Mutalieva HM. Nemotor manifestations in patients with Parkinson's disease. Yuzhno-Rossijskij zhurnal terapevticheskoj praktiki. 2021;2(4):73-78. (In Russ.). https://doi.org/10.21886/2712-8156-2021-2-4-73-78.

7. Dmitrenko DV, Shnayder NA. Teratogenesis of antiepileptic drugs: review of the literature and own observations. Epilepsiya i paroksizmal'nye sostoyaniya. 2014;6(2):61-70. (In Russ.).

8. Dmitrenko D, Shnayder N, Bochanova E, Artyukhov I, Zyryanov S, Veselova O, Gusev S, Potupchik T. Therapeutic drug monitoring in the treatment of epilepsy. Vrach. 2017;1:81-83. (In Russ.).

9. Karlov VA, Kozhokaru AB, Vlasov PN, Pushkar TN, Orlova AS. Dynamics of epileptiform activity, efficacy and tolerability of valproic acid in adults and adolescents with newly-diagnosed epilepsy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(7):35-43. (In Russ.). https://doi.org/10.17116/jnevro202012007135.

10. Karpova VI, Pylaeva OA, Mukhin KYu, Petrukhin AS. Valproic acid and its salts - from the history of discovery to clinical practice (historical sketch). Russkij zhurnal detskoj nevrologii. 2011;3:36-46. (In Russ.).

11. Kirpichenko AA. Modern place of valproates in the treatment of mental and behavioral disorders. Medicinskie novosti. 2022;5(332):34-38. (In Russ.).

12. Levin OS, Artemiev DV, Bril EV, Kulua TK. Parkinson's disease: modern approaches to diagnosis and treatment. Prakticheskaya medicina. 2017;1(102):45-51. (In Russ.).

13. Popova T.E., Tappahov A.A., Govorova T.G., Davydova TK. Nejrodegenerativnye zabolevaniya s preimushchestvennym porazheniem ekstrapiramidnoj sistemy: uchebnoe posobie. Megaprint. 2019. (In Russ.).

14. Smirnova LV, Petukhova OV, Dunayeva MP, Zhdanova NG. Drug monitoring of valproic acid preparations in children with different forms of epilepsy. Politravma. 2008;3:47-50. (In Russ.).

15. Torgan TI, Baidina TV. Non-motor symptoms of Parkinson's disease. Saratovskij nauchno-medicinskij zhurnal. 2012;2:535-538. (In Russ.).

16. Tretyakova NA, Povernova IE. State of postural functions in Parkinson's disease according to computerized stabilometry. Saratovskij nauchno-medicinskij zhurnal. 2011;7(4):874-879. (In Russ.).

17. Shnajder N.A., Vajman E.E., Neznanov N.G., Nasyrova R.F. Farmakogenetika antipsihotik-inducirovannyh ekstrapiramidnyh rasstrojstv. Izdatel'stvo DEAN. 2022. (In Russ.).

18. Shnayder NA, Grechkina VV, Arkhipov VV, Nasyrova RF. Pharmacogenetically-informed pharmacometabolomics as an innovative approach to safety and risk assessment of pharmacotherapy with valproic acid drugs. Bezopasnost' i risk farmakoterapii. 2023;11(4):450-462. (In Russ.). https://doi.org/10.30895/2312-7821-2023-386.

19. Altun Y, Yasar E. Effects of valproate, carbamazepine and levetiracetam on Tp-e interval, Tp-e/QT and Tp-e/QTc ratio. Ideggyogy Sz. 2020;73(3-4):121-127. https://doi.org/10.18071/isz.73.0121.

20. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284-2303. https://doi.org/10.1016/S0140-6736(21)00218-X.

21. Brugger F, Bhatia KP, Besag FM. Valproate-Associated Parkinsonism: A Critical Review of the Literature. CNS Drugs. 2016;30(6):527-40. https://doi.org/10.1007/s40263-016-0341-8.

22. Ricard С, Martin K, Tournier M, Bégaud B, Verdoux H. Troubles cognitifs, syndrome extrapyramidal et hyperammoniémie sous traitement thymorégulateur par divalproate de sodium: à propos d’un cas. L'Encéphale. 2005;31,1:98-101. https://doi.org/10.1016/S0013-7006(05)82378-4.

23. Chouinard G, Cosci F, Chouinard VA, Alphs L. The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties. Psychother Psychosom. 2023;92(6):359-366. https://doi.org/10.1159/000535113.

24. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews. 2013;10: CD003196. https://doi.org/10.1002/14651858.CD003196.pub2.

25. Dal S, Whyte S.Valproate-induced parkinsonism ‘an early warning’: case reports and review of literature. Journal of Neurology, Neurosurgery & Psychiatry. 2019;90:A12. https://doi.org/10.1136/jnnp-2019-anzan.32

26. Elbe D, Glanaghy EM, Oberlander TF. Chapter 3 - Do We Know If They Work and If They Are Safe: Second-Generation Antipsychotics for Treatment of Autism Spectrum Disorders and Disruptive Behavior Disorders in Children and Adolescents. The Science and Ethics of Antipsychotic Use in Children. Academic Press. 2015;27-64. https://doi.org/10.1016/B978-0-12-800016-8.00003-9.

27. Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236-41. https://doi.org/10.1097/FPC.0b013e32835ea0b2.

28. Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1(1):a008862. https://doi.org/10.1101/cshperspect.a008862.

29. Greenland JC, Barker RA. The Differential Diagnosis of Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications; 2018;6. https://doi.org/10.15586/codonpublications.parkinsonsdisease. 2018.ch6.

30. Henderson L, Kennard C, Crawford TJ, Day S, Everitt BS, Goodrich S, Jones F, Park DM. Scales for rating motor impairment in Parkinson's disease: studies of reliability and convergent validity. J Neurol Neurosurg Psychiatry. 1991;54(1):18-24. https://doi.org/10.1136/jnnp.54.1.18.

31. Ho MWR, Chien SHL, Lu MK. et al. Impairments in face discrimination and emotion recognition are related to aging and cognitive dysfunctions in Parkinson’s disease with dementia. Sci Rep. 2020;10:4367. https://doi.org/10.1038/s41598-020-61310-w.

32. Ivey FM, Katzel LI, Sorkin JD, Macko RF, Shulman LM. The Unified Parkinson's Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function. J Rehabil Res Dev. 2012;49(8):1269-76. https://doi.org/10.1682/jrrd.2011.06.0103.

33. Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007; 22(1):130-3. https://doi.org/10.1002/mds.21188.

34. Jochim J, Rifkin‐Zybutz RP, Geddes J, Cipriani A. Valproate for acute mania. Cochrane Database of Systematic Reviews. 2019;10.CD004052. https://doi.org/10.1002/14651858.CD004052.pub2.

35. Lai CL, Lu CC, Lin HC, Sung YF, Wu YP, Hong JS, Peng GS. Valproate is protective against 6-OHDA-induced dopaminergic neurodegeneration in rodent midbrain: A potential role of BDNF up-regulation. J Formos Med Assoc. 2019;118(1 Pt 3):420-428. https://doi.org/10.1016/j.jfma.2018.06.017.

36. Limphaibool N, Iwanowski P, Holstad MJV, Kobylarek D, Kozubski W. Infectious Etiologies of Parkinsonism: Pathomechanisms and Clinical Implications. Front Neurol. 2019;10:652. https://doi.org/10.3389/fneur.2019.00652.

37. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews. 2013;6: CD010611. https://doi.org/10.1002/14651858.CD010611.

38. Luo SX, Huang EJ. Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly. Am J Pathol. 2016;186(3):478-88. https://doi.org/10.1016/j.ajpath.2015.09.023.

39. Muralidharan A, Rahman J, Banerjee D, Hakim Mohammed AR, Malik BH. Parkinsonism: A Rare Adverse Effect of Valproic Acid. Cureus. 2020;12(6):e8782. https://doi.org/10.7759/cureus.8782.

40. Ovchinnikova EV, Vaiman EE, Shnayder NA, Ovchinnikova AA, Nasyrova RF. Classification and Clinical Heterogeneity of Hepatolenticular Degeneration. Personalized Psychiatry and Neurology. 2023;3(2):15-24. https://doi.org/10.52667/2712-9179-2023-3-2-15-24

41. Padmakumar S, Kulkarni P, CF, Bleier BS, Amiji MM. Traumatic brain injury and the development of parkinsonism: Understanding pathophysiology, animal models, and therapeutic targets. Biomedicine & Pharmacotherapy. 2022;149. https://doi.org/10.1016/j.biopha.2022.112812.

42. Sáenz-Farret M, Tijssen MAJ, Eliashiv D, Fisher RS, Sethi K, Fasano A. Antiseizure Drugs and Movement Disorders. CNS Drugs. 2022;36(8):859-876. https://doi.org/10.1007/s40263-022-00937-x.

43. Sekiguchi K, Mashiko T, Koide R, Kawai K, Fujimoto S, Tanaka R. A Case of Long-Term Exposure to Valproic Acid Mimicking Tremor-Dominant Parkinson's Disease. Tremor Other Hyperkinet Mov (N Y). 2023;13:17. https://doi.org/10.5334/tohm.755.

44. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8(1):15-21. https://doi.org/10.3988/jcn.2012.8.1.15.

45. Shiraiwa N, Tamaoka A, Ohkoshi N. Clinical features of drug-induced Parkinsonism. Neurol Int. 2018;10(4):7877. https://doi.org/10.4081/ni.2018.7877.

46. Shnayder NA, Grechkina VV, Khasanova AK, Bochanova EN, Dontceva EA, Petrova MM, Asadullin AR, Shipulin GA, Altynbekov KS, Al-Zamil M, Nasyrova RF. Therapeutic and Toxic Effects of Valproic Acid Metabolites. Metabolites. 2023;13(1):134. https://doi.org/10.3390/metabo13010134.

47. Shrimanker I, Tadi P, Schoo C, et al. Parkinsonism [ncbi.nlm]. ncbi; 2024 [Updated 2024 Mar 13]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542224/

48. Silver M, Stewart A. Factor. Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia. Parkinsonism & Related Disorders. 2013;19(8). https://doi.org/10.1016/j.parkreldis.2013.03.016.

49. Talh AK, Sulaiman M, Joshi D, Hamed S. Development of Parkinsonism symptoms immediately after severe head injury. Neurosciences (Riyadh). 2017;22(4):308-310. https://doi.org/10.17712/nsj.2017.4.20170240.

50. Vaiman EE, Shnayder NA, Khasanova AK, Strelnik AI, Gayduk AJ, Al-Zamil M, Sapronova MR, Zhukova NG, Smirnova DA, Nasyrova RF. Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism. Biomedicines. 2022;10(8):2010. https://doi.org/10.3390/biomedicines10082010.

51. Váradi C. Clinical Features of Parkinson's Disease: The Evolution of Critical Symptoms. Biology (Basel). 2020;9(5):103. https://doi.org/10.3390/biology9050103.

52. Weil RS, Reeves S. Hallucinations in Parkinson's disease: new insights into mechanisms and treatments. Adv Clin Neurosci Rehabil. 2020;19(4):ONNS5189. https://doi.org/10.47795/ONNS5189.

53. Zhang C, Yuan X, Hu Z, Liu S, Li H, Wu M, Yuan J, Zhao Z, Su J, Wang X, Liao Y, Liu Q. Valproic Acid Protects Primary Dopamine Neurons from MPP+-Induced Neurotoxicity: Involvement of GSK3βPhosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway. Biomed Res Int. 2017;2017:8124501. https://doi.org/10.1155/2017/8124501.

54. Zhang Cq, He Bm, Hu Ml and Sun Hb. Risk of Valproic Acid-Related Tremor: A Systematic Review and Meta-Analysis. Front. Neurol. 2020;11:576579. https://doi.org/10.3389/fneur.2020.576579.